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ABSTRACT  
Purpose: Chronic obstructive uropathy can cause irreversible kidney injury, atrophy, and 
inflammation, which can ultimately lead to fibrosis. Epithelial-mesenchymal transition (EMT) is 
a key trigger of fibrosis and is caused by upregulation of transforming growth factor beta 1 
(TGF-β1) and angiotensin II (ANGII). Hydrogen sulfide (H2S) is an endogenously produced 
gasotransmitter with cytoprotective properties. The present study aims to elucidate the effects of 
the slow-releasing H2S donor GYY4137 on chronic ureteral obstruction and evaluate potential 
mechanisms.   
Materials and Methods: Following unilateral ureteral obstruction (UUO), male Lewis rats were 
given daily intraperitoneal (IP) administration of phosphate buffered saline (PBS) vehicle (UUO 
group) or PBS+200µmol/kg GYY4137 (UUO+GYY4137 group) for 30 days. Urine and serum 
samples were collected to determine physiological parameters of renal function and injury. 
Kidneys were removed on post-operative day 30 for evaluation of histopathology and protein 
expression. EMT in pig kidney epithelial cells (LLC-PK1) was induced with TGF-β1 and treated 
with GYY4137 to evaluate potential mechanisms via in vitro scratch wound assays. 
Results: H2S treatment decreased serum creatinine and urine protein/creatinine excretion ratio 
following UUO. In addition, H2S mitigated cortical loss, inflammatory damage, and 
tubulointerstitial fibrosis. Tissues exhibited decreased expression of EMT markers upon H2S 
treatment. EMT progression in LLC-PK1 was alleviated upon in vitro administration of 
GYY4137. 
Conclusions: Our findings demonstrate, for the first time, the protective effects of H2S in 
chronic obstructive uropathy and may represent a potential therapeutic solution to ameliorate 
renal damage and improve clinical outcomes of urinary obstruction.  
Key words: Hydrogen sulfide; Chronic obstructive uropathy; Epithelial-mesenchymal transition; 
Angiotensin II; Transforming growth factor β-1 
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INTRODUCTION 
 Obstructive uropathy affects approximately 10% of Americans1. If left untreated, it can 
lead to inflammation, atrophy, fibrosis, and irreversible renal injury ending in chronic kidney 
disease2, which can significantly burden both patients and the health care system3.  
A proposed mechanism of obstructive uropathy postulates that injured kidney epithelial 
cells express cytokines that lead to leukocyte infiltration. These leukocytes subsequently release 
a variety of mediators such as transforming growth factor beta-1 (TGF-β1)2. Regulated by 
angiotensin II (ANGII)4, TGF-β1 is an inducer of epithelial-mesenchymal transition (EMT), a 
key initiator of tissue fibrosis. Tubulointerstitial fibrosis can lead to tissue damage, loss of 
function and irreversible injury5,6.  
While effective surgical and non-surgical procedures are available to abrogate urinary 
obstruction, patients can experience long wait times between initial consultation and medical 
intervention, ultimately causing renal injury to accumulate. Current pharmacological treatments 
aimed at limiting renal injury during obstruction are scarce. Recent evidence suggests that 
gasotransmitters (small, endogenously-produced gaseous molecules) can exhibit anti-
inflammatory and vasodilatory effects in tissue injury7,8. H2S is endogenously produced by 
cystathionine β-synthase, cystathionine γ-lyase, and 3-mercaptopyruvate sulfurtransferase, and 
can mediate cellular signaling, vasodilation, apoptosis and inflammation8.  
Two recent studies have demonstrated that exogenous H2S, released via sodium 
hydrosulfide (NaHS), can ameliorate damage associated with short-term ureteral obstruction9,10. 
While histopathological analyses were performed, these studies did not evaluate functional 
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changes. Additionally, as NaHS generates supra-physiological quantities of H2S spontaneously 
in solution and has a half-life of only 15 minutes, it is a difficult potential therapeutic tool. 
GYY4137 is an H2S donor molecule that allows for slow and extended release of H2S over a 24-
hour period11. Unlike NaHS, GYY4137 results in a sustained elevation of plasma  H2S  levels 
upon intraperitoneal (IP) and intravenous (IV) administration11. GYY4137 also possesses 
significant anti-inflammatory, anti-oxidant and anti-apoptotic characteristics, as demonstrated by 
our lab and others, which makes it an ideal potential therapy against renal injury12–15. 
 In the present study, we examined the effects of daily supplemental GYY4137 on serum 
biochemistry, glomerular function and histopathological parameters associated with a rat model 
of chronic unilateral ureteral obstruction (UUO)5. We evaluated the potential mechanisms behind 
our findings by examining tissue protein expression and via an in vitro scratch assay16. We 
demonstrate, for the first time, that exogenous H2S treatment during chronic ureteral obstruction 
can preserve overall renal function, decrease inflammatory damage and attenuate fibrosis via a 
TGF-β1- and ANGII-mediated mechanism. Thus, H2S supplementation is a potential therapy in 
the management of ureteral obstruction.  
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MATERIALS AND METHODS 
Animal description and care 
Adult male Lewis rats (250g – 300g; Charles River Laboratories International Ltd.) were 
maintained in the Animal Care and Veterinary Services facility at The University of Western 
Ontario (UWO) in accordance with conditions outlined by the Committee on Care and Use of 
Laboratory Animals of the Institute of Laboratory Animal Resources, National Research 
Council. The surgical protocols were approved by the Council on Animal Care and Animal Use 
Subcommittee of UWO. 
Unilateral ureteral obstruction (UUO) procedure and postoperative monitoring 
UUO is a common model used to simulate obstruction and induce fibrosis5. Rats were 
randomly divided into four groups: Sham (n=5), Sham+GYY4137 (n=5), UUO (n=8), and 
UUO+GYY4137 (n=7). All rats were anesthetized with ketamine and isoflurane. Sham rats 
underwent an abdominal incision and closure. To permanently ligate the left ureter in the UUO 
and UUO+GYY4137 groups, silk ties were placed across the left ureteropelvic junction. All 
animals were monitored for 30 days post-operatively.  Animals in the UUO group were 
administered daily IP injections of phosphate buffered saline (PBS) vehicle (0.1 mL). 
UUO+GYY4137 and Sham+GYY4137 animals were given daily IP injections of GYY4137 (200 
µmol/kg GYY4137 in 1 mL PBS; 1mL of PBS was required to dissolve GYY4137). GYY4137 
was not dissolved in DMSO as it was being injected over an extended period of time.  While this 
minimized toxicity, it may have limited the efficacy of the drug. On post-operative day (POD) 3, 
10, 20 and 30, urine and serum samples were collected to analyze renal function. Urine protein 
and creatinine and serum creatinine (SCr) levels were measured using the Roche Modular P 
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instrument. At the time of sacrifice (POD30), kidneys were removed and divided sagittally, with 
each half used for either histological or quantitative real-time polymerase chain reaction (qRT-
PCR) and Western Blot analysis. 
Histological staining  
Tissues were fixed in 10% formalin, embedded in paraffin and sectioned. Sections were 
stained with Masson’s trichrome and terminal deoxynucleotidyl-transferase-mediated dUTP nick 
end labeling (TUNEL) to assess fibrosis and apoptosis, respectively. Immunohistochemical 
(IHC) staining with antibodies against CD68 (Abcam) and myeloperoxidase (MPO, Abcam) were 
used to determine macrophage and neutrophil infiltration, respectively. Sections were stained 
with hematoxylin and eosin (H&E) to determine cortical thickness. 
Image Analysis 
In a blinded fashion, TUNEL, IHC and Masson’s trichrome sections were imaged using a 
Nikon Eclipse 90i light microscope at 10x magnification at 5 random areas. Using ImageJ 
software (National Institutes of Health), the number of positive cells per field of view (FOV) was 
quantified for TUNEL and IHC sections, and percent fibrosis per FOV was quantified for 
trichrome sections. Analysis of each kidney was completed using median counts of positive cells 
and median percent fibrosis. H&E sections were whole-slide scanned with ScanScope AT Turbo 
Aperio (Leica Biosystems); cortical thickness was measured by a blinded pathologist and 
normalized: 
Relative	cortical	thickness = 	 Cortical	thicknessMean	cortical	thickness	of	Sham	kidneys	 
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Quantitative RT-PCR Analysis 
 Using the Ambion PARIS kit (Life Technologies), total RNA was extracted from renal 
tissue and reverse transcribed into cDNA using SuperScript VILO MasterMix (Life 
Technologies) as per manufacturer’s protocol. Concentrations were determined using NanoDrop 
1000 Spectrophotometer (Thermo Scientific). qPCR was performed using Fast SYBR Green PCR 
Master Mix (Life Technologies) and analyzed using CFX96 Real Time System thermal cycler 
and CFX Manager Software (Bio-rad Laboratories). Primer sequences were designed using 
PrimerQuest (Integrated DNA Technologies) against glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), ANGII receptor type 1 (ANGIIR1), fibronectin, vimentin, TGF-β1, TGF-β1 receptor 
2 (TGF-β1R2) and Smad2 (Table 1). GAPDH served as a reference gene, and fold-change in 
gene expression was calculated via the ∆∆Ct method.  
Western Blot Analysis 
 Total protein was extracted from kidney homogenate using the Ambion PARIS kit (Life 
Technologies) as per manufacturer’s protocol. Lysate concentrations were quantified using the 
NanoDrop 1000 Spectrophotometer ( hermo Scientific). 30 µg of protein was separated by SDS-
PAGE, transferred onto a nitrocellulose membrane and probed with antibodies against β-actin 
(Santa Cruz Biotechnology), vimentin, GAPDH and TGF-β1R2 (GeneTex). Secondary 
antibodies were Horseradish peroxidase-linked anti-rabbit or anti-mouse (GeneTex). Proteins 
were detected using ImmunStar Western C (Bio-rad Laboratories). Chemiluminescent signals 
were detected and analyzed with FluorChem M System (Protein Simple).  
Cell culture and treatment 
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Pig kidney epithelial cells (LLC-PK1, ATCC) were cultured in Gibco Medium 199 (Life 
Technologies) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 
37oC under 5% CO2.   
In vitro scratch wound assay 
In vitro scratch wound assays were performed to investigate the effects of GYY4137 on 
the migratory properties of EMT16. In 24-well plates, LLC-PK1 cells were seeded at 1.25x105 
cells/well, allowed to reach 90% confluency, then serum starved for 24 hours. To create a 
wound, the monolayer was scratched with a 200 µL micropipette tip and washed with serum-free 
Medium 199. Cells were treated with 10 ng/mL TGF-β1 (Peprotech), 10 µM GYY4137, 50 µM 
GYY4137, 10 ng/mL TGF-β1+10 µM GYY4137, 10 ng/mL TGF-β1+50 µM GYY4137 or 
untreated in serum-free Medium 199.  Under standard culture conditions, the scratch wound was 
imaged every hour for 72 hours using IncuCyte ZOOM (Essen Bioscience). Area of scratch 
wound was quantified with ImageJ software (National Institutes of Health) and rate of migration 
was calculated with the following formula: 
Rate	of	migration =
1 −	scratch	area	at	72hscratch	area	at	0h  × 100%
Average	migration	of	untreated	cells 
Statistical Analysis 
Data in figures are presented as mean ± standard error of mean (SEM). ANOVA and 
post-hoc Tukey’s HSD were performed to determine statistical difference between multiple 
groups. Student’s unpaired t-test was performed to determine significance at individual time 
points (GraphPad Prism v6.0, USA). Statistical significance was accepted at the 95% confidence 
interval.  
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RESULTS 
GYY4137 treatment decreased serum creatinine and proteinuria during chronic UUO. 
SCr was significantly higher on POD3 in both UUO and UUO+GYY4137 when 
compared to Sham (p<0.01, p<0.0001). However, SCr of UUO+GYY4137 decreased to Sham 
levels on POD10, whereas SCr of UUO group remained elevated until POD20 (p<0.05). SCr of 
UUO and UUO+GYY4137 remained similar to Sham on POD20 and POD30 (Figure 1A).  
Interestingly, urine protein to creatinine excretion ratio (UPr/Cr) of UUO group was significantly 
higher compared to Sham on POD3 (p<0.05) and remained slightly elevated until POD30, 
whereas the UUO+GYY4137 group demonstrated normal UPr/Cr throughout the experiment 
(Figure 1B). No differences in SCr and UPr/Cr were observed between Sham+GYY4137 and 
Sham animals (Figure 1). 
GYY4137 treatment did not affect long-term apoptosis  
TUNEL stain was used to determine the level of apoptosis. At POD30, all groups 
exhibited similar levels of apoptosis (Figure 2).  
GYY4137 retained renal cortical thickness following long-term obstruction 
Tissue sections were stained with H&E, and cortical thickness was measured (Figure 3A, 
representative images). On POD30 following UUO, there was a significant decrease in cortical 
thickness in both treatment groups when compared to the Sham animals (p<0.0001). However, 
the daily administration of GYY4137 was protective and led to a lesser decline in cortical 
thickness compared to the UUO group treated with vehicle (p<0.05) (Figure 3B).  No difference 
in renal cortical thickness was observed between Sham and Sham+GYY4137 groups (Figure 3). 
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GYY4137 did not affect long-term inflammation 
 Kidney sections were immunohistochemically stained with antibodies against 
macrophage marker CD68 and neutrophil marker MPO. The number of CD68-positive cells in 
the UUO and UUO+GYY4137 were elevated compared to Sham (p<0.01) on POD30 (Figure 
4A). There was a slight increase in neutrophil infiltration in both UUO and UUO+GYY4137 
groups compared to Sham (p=0.101 and p=0.515, respectively), although the effects appeared to 
be slightly blunted in the UUO+GYY4137 group (Figure 4B). Sham and Sham+GYY4137 
groups displayed similar levels of inflammatory infiltrate (Figure 4). 
Supplemental GYY4137 mitigated renal fibrosis during chronic UUO 
Fibrosis was detected through histological staining with Masson’s trichrome, with 
fibrotic areas staining blue (Figure 5A).  On POD30, there was a significant increase in the 
percent fibrosis of the obstructed kidney in the UUO group (p<0.001) which was significantly 
decreased to Sham levels in the UUO+GYY4137 animals (p<0.01) (Figure 5B). We observed no 
difference in renal fibrosis between Sham and Sham+GYY4137 groups (Figure 5). 
GYY4137 attenuated migration associated with EMT 
To assess the effect of GYY4137 on the migratory properties of EMT, a scratch wound 
assay was performed. Migration was determined based on the rate of wound closure and 
presented as a fold change relative to the control.  Treatment with 10 ng/mL TGF-β1 increased 
migration in LLC-PK1 cells when compared to untreated control (p=0.131, Figure 6).  TGF-β1-
induced migration was significantly decreased upon treatment with 10 µM GYY4137 and 50 µM 
GYY4137 (p<0.05, Figure 6).  
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GYY4137 mitigated expression of EMT inducers and markers 
 Expression of EMT markers were determined through qRT-PCR analysis of left kidney 
tissue obtained at POD30. Upregulation of ANGIIR1, TGF-β1, TGF-β1R2, Smad2, Col1α1, 
fibronectin and vimentin were observed in both UUO and UUO+GYY4137 groups when 
compared to Sham. Interestingly, the UUO+GYY4137 group demonstrated a significant decrease 
in expression of ANGIIR1, Col1α1, fibronectin, vimentin, and Smad2 (p<0.05), and a marked 
decrease in expression of TGF-β1 and TGF-β1R2 when compared to UUO (Figure 7). Western 
Blot analysis at POD30 (Figure 8A) showed increased TGF-β1R2 and vimentin expression in 
UUO and UUO+GYY4137 groups when compared to Sham (p=0.096 and p=0.100, 
respectively). In keeping with the mRNA expression, both TGF-β1R2 and vimentin responses 
were diminished in the UUO+GYY4137 group when compared to UUO group (p=0.478 and 
p=0.846, respectively; Figure 8B).  
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DISCUSSION 
Recent studies have identified H2S as an endogenous gasotransmitter and a key 
modulator of physiological responses. In the kidney, H2S plays a critical role in regulating renal 
function, fibrosis and inflammation7,8,17. Here, we examined the effects of the H2S donor 
GYY4137 on a chronic model of UUO. We found that the exogenous administration of a long-
acting H2S donor alleviated tissue injury associated with chronic obstruction. 
Immediately following UUO, SCr in both UUO and UUO+GYY4137 groups were 
significantly elevated when compared to Sham. This was unexpected, as the contralateral kidney 
typically compensates for the function of the obstructed kidney. However, SCr levels of 
UUO+GYY4137 group returned to basal levels on POD10, while SCr levels of UUO group 
remained elevated. Due to its vasodilatory properties, one potential explanation for these findings 
is based on the ability of H2S to divert blood flow to the contralateral kidney through afferent 
arteriolar dilation (reno-renal reflex)8,18.  Additionally, high doses of ketoprofen were 
administered on POD1 and POD2 to minimize the discomfort from complete UUO; its 
nephrotoxic effects were reflected in the decreased glomerular filtration rate (data not shown) in 
both UUO and UUO+GYY4137 groups on POD3, and UUO group only on POD10. Therefore, it 
is likely that the nephrotoxic properties of ketoprofen masked the early remedial effect of 
GYY4137.  Interestingly, UUO+GYY4136 group exhibited significantly lower UPr/Cr on 
POD10 and slightly decreased UPr/Cr on all other PODs when compared to UUO group. As 
proteinuria can be seen following hyperfiltration and hypertensive injury19, these findings 
demonstrate the well-established ability of H2S to mediate intra-renal pressure8. Remarkably, this 
was also reflected in our analysis of ANGIIR1 expression on POD30, which was significantly 
decreased upon treatment with GYY4137. Our data not only demonstrate the detrimental effects 
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of UUO on overall renal function in a healthy subject, but also highlight that H2S can mitigate 
renal injury by decreasing pressure in the obstructed kidney via dilation of the efferent arteriole.  
The anti-apoptotic properties of H2S have been well-documented in many previous 
studies20,21. We examined the effects of H2S on renal apoptosis following obstruction via 
TUNEL staining and observed similar levels of apoptosis across all treatment groups. Previous 
studies have observed an acute increase in renal tubular apoptosis following UUO with a 
trending decline shortly thereafter, suggesting the initiation of a more fibrotic phenotype22. This 
fits well with our findings at 30 days post-UUO and highlights the importance of early 
decompression of the renal moiety. Future studies evaluating the reversibility of this phenotype 
are warranted, especially in light of our novel findings with exogenous H2S supplementation as a 
potential therapeutic strategy in UUO.  
H&E sections revealed a decrease in cortical thickness of UUO and UUO+GYY4137 
kidneys when compared to Sham. This is attributable to tissue atrophy and nephron loss and is an 
indication of irreversible kidney injury23,24. Similar to previous studies, the administration of H2S 
significantly diminished cortical loss of the obstructed kidney. However, our studies showed a 
more marked benefit, likely due to our use of GYY4137, a more long-acting H2S donor 
compared to the sodium salts employed by other groups10. Our results demonstrate that 
exogenous H2S may play a protective role in the face of cortical loss during chronic obstruction. 
Interestingly, we also observed an increase in cortical thickness of the contralateral kidney in 
UUO group, but not UUO+GYY4137 group, when compared to Sham. This compensatory 
hypertrophy of the contralateral kidney is typically observed following UUO and is often 
associated with hyperfiltration23,25, which may explain the parallel increase in UPr/Cr observed 
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in UUO group. Our data demonstrate that GYY4137 may exert protective effects on both 
kidneys to alleviate renal injury. 
TGF-β1 is a cytokine released by inflammatory cells and can cause fibrosis26. Through 
IHC, we examined the level of inflammatory infiltrate following UUO and found elevated levels 
of CD68-positive and MPO-positive cells. Although H2S did not reduce macrophage infiltration, 
the slight decrease in neutrophil infiltration in UUO+GYY4137 group confirms the anti-
inflammatory actions of H2S15,20. Previous studies found higher levels of CD68 infiltration at 
higher dosages of NaHS9, which concurred with the results obtained from our study. 
Additionally, CD68 is a marker for both M1 and M2 macrophages, with pro- and anti-
inflammatory effects, respectively. As M2 macrophages play a critical role in kidney repair27, 
increase in CD68-positive cells may therefore reflect a surge of anti-inflammatory M2 cells.  
UUO+GYY4137 animals also exhibited a significant decrease in fibrosis when compared to 
UUO group, which paralleled our inflammatory phenotype observations. Our data imply that 
exogenously administered H2S can abate fibrotic injury associated with long-term obstruction, 
possibly through modulation of the TGF-β1/Smad pathway.   
The TGF-β1/Smad pathway is regulated by ANGII, an inducer of TGF-β1 expression4. 
This pathway is a major mediator of fibrosis as it activates EMT, thereby causing epithelial cells 
to migrate28. We sought to investigate the effects of H2S on EMT-induced migration in kidney 
epithelial cells using an in vitro scratch assay. We observed a trend towards increased migration 
in LLC-PK1 cells upon treatment with TGF-β1, which was attenuated upon addition of 
GYY4137.  Echoing our in vitro results, we observed elevated expressions of ANGIIR1, TGF-β1 
and other EMT markers in our UUO group, which were consistently alleviated upon 
administration of GYY4137. These trends were also reflected in our Western Blot analysis of 
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EMT markers, which demonstrated a marked downregulation in UUO+GYY4137 when 
compared to UUO. Taken together, our results imply that H2S can mitigate renal fibrosis through 
attenuation of EMT.  
While recent studies have demonstrated increased detrusor smooth muscle contractility 
upon GYY4137 administration29, vesico-ureteral reflex was not observed in our GYY4137-
treated animals. Fernandes et al. had administered 0.1 nM of GYY4137, therefore generating 
picomolar of H2S; such minute amounts of H2S is unlikely to induce observable effects. 
Additionally, they dissolved GYY4137 in dichloromethane-containing (and thus carbon 
monoxide-generating) DMSO29, which may also explain this discrepancy. Furthermore, as no 
functional or histological differences were observed between Sham and Sham+GYY4137 
groups, we conclude that daily IP administration of GYY4137 in PBS does not induce changes in 
a healthy kidney.  
In conclusion, the administration of exogenous H2S exerts protective effects against renal 
injury in a multifaceted manner. H2S appears to alleviate renal inflammation, preserve 
architecture, and improve overall renal function. We have also demonstrated that GYY4137 
plays a critical role in mitigating renal fibrosis by attenuating TGF-β1-induced EMT through 
mediating renal hypertension and ANGIIR1 expression. Our findings have important clinical 
implications as H2S may be a preemptive therapy against renal damage and can ultimately 
improve outcomes for patients with obstructive uropathy.  
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FIGURE LEGENDS 
Figure 1. Exogenous GYY4137 treatment improved renal function and decreased renal 
injury during long-term obstruction.  On post-operative days 3, 10, 20 and 30, urine and 
serum samples were collected from Sham (n=5), Sham + GYY4137 (n=5, 200 µmol/kg 
GYY4137 in 1 mL PBS, IP daily), UUO (n=8, 0.1 mL PBS, IP daily), and UUO+ GYY4137 
(n=7, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily) groups for analysis of A) serum creatinine 
levels and B) urine protein/creatinine excretion ratios (UPr/Cr). Values are normalized to body 
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weight on date of data collection. Data represents mean ± SEM. * p<0.05 compared to Sham and 
†p<0.05 compared to UUO.  
Figure 2. GYY4137 treatment did not affect apoptosis following chronic UUO. Kidneys 
samples collected on post-operative day 30 from Sham (n=5), UUO (n=8, 0.1 mL PBS, IP daily), 
and UUO+GYY4137 (n=7, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily) animals were stained 
with TUNEL. Median counts of positively stained cells per FOV at 10x magnification were 
determined. Each data point represents median cell count of kidney; bar represents mean. 
Figure 3. Supplemental GYY4137 preserved renal cortical thickness following long-term 
UUO. Kidney samples were collected following Sham operations (n=5), Sham+GYY4137 (n=5, 
200 µmol/kg GYY4137 in 1 mL PBS, IP daily), UUO (n=8, 0.1 mL PBS, IP daily), and 
UUO+GYY4137 treatment (n=7, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily) at 30 days 
post-operation.  A) Representative whole-slide scan of tissues stained with H&E. B) Cortical 
thickness was measured by a blinded pathologist. Measurements were normalized to mean Sham 
cortical thickness of the ipsilateral kidney. Values are mean ± SEM. * p<0.05 compared to 
Sham, † p<0.05 compared to UUO. Note: Omission of an outlier with relative cortical thickness 
of 0.804 in UUO. 
Figure 4. GYY4137 did not decrease infiltration of inflammatory cells following chronic 
UUO. Kidney tissues were obtained at 30 days post-Sham (n=5), Sham+GYY4137 (n=5, 200 
µmol/kg GYY4137 in 1 mL PBS, IP daily), UUO (n=8, 0.1 mL PBS, IP daily), and 
UUO+GYY4137 (n=7, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily) for 
immunohistochemical analysis. A) Antibody against CD68 was used to detect presence of 
macrophages and B) antibody against MPO was used to detect presence of neutrophils at 10x 
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magnification. Positively stained cells were quantified with ImageJ software. Data represents 
mean cell count ± SEM.  * p<0.05 compared to Sham 
Figure 5. GYY4137 treatment decreased renal fibrosis following 30-day UUO. Masson’s 
trichrome staining of kidneys 30 days after Sham (n=5), Sham+GYY4137 (n=5, 200 µmol/kg 
GYY4137 in 1 mL PBS, IP daily), UUO (n=8, 0.1 mL PBS, IP daily), and UUO+GYY4137 
treatment (n=7, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily). A) Representative images of 
kidneys stained for fibrotic tissue at 10x magnification. B) Median percent fibrotic area at 10x 
magnification was analyzed. Values are mean ± SEM. * p<0.05 compared to Sham, † p<0.05 
compared to UUO. 
Figure 6. GYY4137 treatment resulted decreased TGF-β1-induced migration.  Scratch 
wound was created in a monolayer of LLC-PK1 cells in the presence of 10 ng/mL TGF-β1, 10 
µM GYY4137, 50 µM GYY4137, 10 ng/mL TGF-β1+10 µM GYY317, 10 ng/mL TGF-β1+50 
µM GYY417 or untreated in serum free media (n=4), and migration was observed at 0 and 72 
hour post-scratch. Fold change in migration relative to untreated control cells was determined at 
72 hours post-scratch. Data represents mean ± SEM. * p<0.05 compared to 10ng/mL TGF-β1 
Figure 7. GYY4137 treatment decreased expression of genes in the epithelial-mesenchymal 
transition pathway. Kidney homogenates of Sham (n=3), UUO (n=3, 0.1 mL PBS, IP daily), 
and UUO+GYY4137 (n=3, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily) were collected 30 
days post-obstruction. Quantitative real-time polymerase chain reaction (qRT-PCR) analysis was 
performed on homogenates to determine expression of genes upstream and within the epithelial-
mesenchymal transition (EMT) pathway. mRNA expressions of angiotensin II receptor type I 
(ANGIIR1), transforming growth factor β1 (TGF-β1), TGF-β1 receptor 2 (TGF-β1R2), Smad2, 
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collagen 1 alpha 1 (Col1α 1), fibronectin, and vimentin were determined.  Target gene 
expression was normalized to GAPDH, and fold change in expression was determined relative to 
Sham. Data are mean ± SEM. *p<0.05 compared to Sham and †p<0.05 compared to UUO 
Figure 8. Exogenous GYY4137 partially diminished expression of TGF-β1 receptor 2 and 
vimentin in chronic model of UUO.  A) SDS-PAGE and vimentin and TGF-β1R2 Western 
blotting of 30 µg of kidney lysate from Sham (n=3), UUO (n=3, 0.1 mL PBS, IP daily), and 
UUO+GYY4137 treatment (n=3, 200 µmol/kg GYY4137 in 1 mL PBS, IP daily). GAPDH 
served as loading control for TGF-β1R2 blot and β-actin served as a loading control for vimentin 
blot.  B) Chemiluminescent signals were quantified. TGF-β1R2 expression was normalized to 
GAPDH and vimentin expression was normalized to β-actin.  Values were normalized to Sham 
expression of respective protein. Values are depicted in bar graph. UUO dramatically increased 
expression of TGF-β1R2 and vimentin, and H2S treatment modestly decreased their expression. 
Data are mean ± SEM.  
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1. qRT-PCR Primers 
Genes Primers 
GAPDH Forward: ACTCCCATTCTTCCACCTTTG 
Reverse: CCCTGTTGCTGTAGCCATATT 
ANGIIR1 Forward: TGTCATGATCCCTACCCTCTAC  
Reverse: GCCACAGTCTTCAGCTTCAT 
TGF-β1 Forward: CTGAACCAAGGAGACGGAATAC 
Reverse: GTTTGGGACTGATCCCATTGA 
TGF-β1R2 Forward: CTGACCTGTTGCTGGTCATTA 
Reverse: GTGGACACGGTAACAGTAGAAG 
Smad2 Forward: GCCTAAGTGATAGTGCGATCTT 
Reverse: GTTACAGCCTGGTGGGATTT 
Col1α1 Forward: ACTGGTACATCAGCCCAAAC 
Reverse: GGAACCTTCGCTTCCATACTC 
Fibronectin Forward: CCAAGTACATTCTCAGGTGGAG  
Reverse: GGTCAGGCCTTTGATGGTATAG 
Vimentin Forward: CCATCAACACCGAGTTCAAGA 
Reverse: CGCACCTTGTCGATGTAGTT 
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ABBREVIATIONS 
Transforming growth factor beta-1 (TGF-β1); Angiotensin II (ANGII); Epithelial-mesenchymal 
transition (EMT); Sodium hydrosulfide (NaSH); Intraperitoneal (IP); Intravenous (IV); 
Unilateral ureteral obstruction (UUO); University of Western Ontario (UWO); Phosphate 
buffered saline (PBS); Post-operative day (POD); quantitative real-time polymerase chain 
reaction (qRT-PCR); Terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling 
(TUNEL); Immunohistochemical (IHC); Field of view (FOV); Myeloperoxidase (MPO); 
Hematoxylin and eosin (H&E); Glyceraldehyde 3-phosphate dehydrogenase (GAPDH); 
Angiotensin II receptor type 1 (ANGIIR1); Transforming growth factor β1 receptor 2 (TGF-
β1R2); Horseradish peroxidase (HRP); Gibco Medium 199 (M199); standard error of mean 
(SEM); Serum creatinine (SCr); Urine protein/creatinine excretion ratio (UPr/Cr);  
 
 
